Early Therapeutic Antibody Development: Addressing the Challenges to Expedite a CMC Program.

Learn how de-risk early-stage CMC and delivery of clinical trials material by addressing the challenges faced when therapeutic antibodies show less-than-ideal properties, from early development through to downstream manufacturing to pre-clinical and clinical studies.

Access the full on-demand webinar from our team of industry experts as they take an in-depth look at their area of specialism.